Kringle Pharma, Inc.

2026/11/16 20:00 Updated
Market Cap: $26.8M (¥4.3B)
Stock Price: $3.32 (¥529)
Exchange Rate: 1 USD = ¥159.49

Q&A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026

Published a summary of the Q&A from the full-year financial results briefing for the fiscal year ended September 2026. Key discussion points included preparing the U.S. spinal cord injury development for a Ready-to-Go state, establishment of HGF active pharmaceutical ingredient (API) manufacturing, progress and data disclosure timing for the vocal fold scarring treatment Phase III, orphan designation progress, funding plan and approximately 2.2 billion yen use of proceeds, collaboration versus in-house development strategy, and strategic shareholders’ investment purposes and potential for long-term holding.

Importance:
Page Updated: November 17, 2026
IR Disclosure Date: November 17, 2026

Key Figures

  • Costs to advance U.S. Phase III trial preparations: approx. 678 million yen
  • Construction of HGF API manufacturing capability using new manufacturing method: approx. 640 million yen
  • Domestic HGF API manufacturing: approx. 310 million yen

AI要約

Business Development and R&D Investment Explanation

The company clarified its policy to advance preparations for the Phase III acute spinal cord injury trial in the U.S. to a Ready-to-Go state. It will carry out funding to accelerate trial initiation and explore non-dilutive funding and partnership-based financing options. The policy is to pursue clinical development and manufacturing in parallel, including building HGF API manufacturing capabilities, establishing U.S. manufacturing infrastructure, and preparing for the regulatory filing for the vocal fold scarring treatment.

Funding and Capital Policy

The plan targets fundraising on the order of 2.2 billion yen to promote preparation for the U.S. Phase III trial, construct HGF API manufacturing capabilities using a new manufacturing method, and cover domestic manufacturing costs and working capital. The exercise price structure is two-tiered, with 1,000 yen reflecting a market capitalization exceeding 10 billion yen and aligning with IPO offering price considerations. Investments from strategic shareholders Maruishi Pharmaceutical and Xenoack Holdings signify understanding of the business strategy and continued support.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Kringle Pharma, Inc.

Company overview · Stock price · Financial data · All IR

View company page →